MX2019005140A - Exosomas y usos de los mismos en enfermedades del cerebro. - Google Patents
Exosomas y usos de los mismos en enfermedades del cerebro.Info
- Publication number
- MX2019005140A MX2019005140A MX2019005140A MX2019005140A MX2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A MX 2019005140 A MX2019005140 A MX 2019005140A
- Authority
- MX
- Mexico
- Prior art keywords
- exosomes
- brain
- disease
- attendant
- medicaments
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title abstract 6
- 210000004556 brain Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000014644 Brain disease Diseases 0.000 abstract 3
- 208000029028 brain injury Diseases 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000025698 brain inflammatory disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000003909 pattern recognition Methods 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 208000005809 status epilepticus Diseases 0.000 abstract 1
- 208000023516 stroke disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen medicamentos y métodos para inhibir la inflamación cerebral y la pérdida de memoria cognitiva por enfermedad y daño cerebral en un animal. El estado epiléptico, apoplejía y enfermedad de Alzheimer son patologías particulares que se tratan empleando preparaciones farmacéuticamente aceptables de los exosomas Al. Las preparaciones comprenden una población enriquecida de exosomas Al, tal como exosomas derivados de medio de cultivo de células madre mesenquimales. Los medicamentos y métodos para inhibir el reconocimiento de patrones y/o deterioro de memoria por un evento de lesión cerebral o enfermedad cerebral degenerativa también se describen, que comprenden administrar una preparación farmacéuticamente aceptable de exosomas, particularmente exosomas Al, que son CD9- y que previenen la elevación de citocinas pro-inflamatorias por lesión cerebral o enfermedad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416638P | 2016-11-02 | 2016-11-02 | |
| PCT/US2017/059787 WO2018085587A1 (en) | 2016-11-02 | 2017-11-02 | Exosomes and uses thereof in diseases of the brain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005140A true MX2019005140A (es) | 2020-01-20 |
Family
ID=62076165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005140A MX2019005140A (es) | 2016-11-02 | 2017-11-02 | Exosomas y usos de los mismos en enfermedades del cerebro. |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220175842A1 (es) |
| EP (1) | EP3534918A4 (es) |
| MX (1) | MX2019005140A (es) |
| WO (1) | WO2018085587A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL259470B (en) | 2015-11-18 | 2022-08-01 | Univ Georgia | Extracellular vesicles of nerve cells |
| WO2020215158A1 (en) * | 2019-04-26 | 2020-10-29 | Braun Janice E A | Method and vehicle for delivering agents across the blood-brain barrier |
| CN113082058A (zh) * | 2021-03-19 | 2021-07-09 | 瑞太生物科技(沈阳)有限公司 | 一种细胞来源的外泌体在制备治疗阿尔茨海默病生物制剂中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013039000A1 (ja) * | 2011-09-13 | 2015-03-26 | 孝広 落谷 | アルツハイマー病の予防または治療のための医薬品 |
| US9919011B2 (en) * | 2014-03-18 | 2018-03-20 | Samsung Life Public Welfare Foundation | Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome |
| AU2015264519B2 (en) * | 2014-05-18 | 2021-01-28 | Children's Medical Center Corporation | Methods and compositions relating to exosomes |
| US11160834B2 (en) * | 2015-04-28 | 2021-11-02 | The Texas A&M University System | Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof |
-
2017
- 2017-11-02 WO PCT/US2017/059787 patent/WO2018085587A1/en not_active Ceased
- 2017-11-02 US US16/346,806 patent/US20220175842A1/en not_active Abandoned
- 2017-11-02 EP EP17867128.5A patent/EP3534918A4/en not_active Withdrawn
- 2017-11-02 MX MX2019005140A patent/MX2019005140A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018085587A1 (en) | 2018-05-11 |
| EP3534918A4 (en) | 2020-07-22 |
| US20220175842A1 (en) | 2022-06-09 |
| EP3534918A1 (en) | 2019-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002321A (es) | Nuevos metodos. | |
| JOP20220092A1 (ar) | جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MY187358A (en) | Modified release orally administered amino acid formulations | |
| SG10201803862UA (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| NZ785158A (en) | Topical cyclosporine-containing formulations and uses thereof | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| MX2017013852A (es) | Produccion escalable de vesiculas extracelulares estandarizadas, preparaciones de vesiculas extracelular y usos de estos. | |
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| MX2019002518A (es) | Metodos y vectores para el tratamiento de trastornos del snc. | |
| WO2015171965A3 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| MX2022003128A (es) | Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. | |
| MY204563A (en) | Pharmaceutical compositions containing anti-beta amyloid antibodies | |
| MX2022004759A (es) | Métodos y composiciones para tratar enfermedades y trastornos hepáticos. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| NZ754020A (en) | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same | |
| MX2019005140A (es) | Exosomas y usos de los mismos en enfermedades del cerebro. | |
| EP4613333A3 (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors | |
| WO2018115432A3 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| MX2018009189A (es) | Compuestos de anillo de siete miembros de pirimidina. | |
| WO2012158405A3 (en) | Compositions and methods for the treatment of skin diseases | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib |